• NEBANNER

Fixed Competitive Price K Series Polyacrylamide - 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3 – JIN DUN

Fixed Competitive Price K Series Polyacrylamide - 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3 – JIN DUN

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We are committed to providing easy,time-saving and money-saving one-stop purchasing service of consumer for Tertiary Treatment Of Water, Composite Leakage Agent, Boiler Treatment Chemicals, Together with our efforts, our products have won the trust of customers and been very salable both here and abroad.
Fixed Competitive Price K Series Polyacrylamide - 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3 – JIN DUN Detail:

Use: Intermediate for Linagliptin.

Use:Intermediate for Linagliptin
Executive standard: enterprise standard
Assay:98-102%

Exterior:White to light yellow powder
Package: 25kg/drum

To analyze the existing linagliptin and its key intermediate 8-bromo-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl -2-quinazolinyl)methyl)-1H-purine-2,6-dione (11) synthesis method, find a synthetic route suitable for industrial production. Method: summarize the different synthetic routes. Results and conclusions: Route 2.2 has a relatively simple process and lower cost, which is more suitable for industrial production.

8-bromo-3,7-dihydro-3-methyl-1H-purine-2,6-dione is a key intermediate in the synthesis of the hypoglycemic drug linagliptin. The synthesis of 1 uses methyl urea and cyanoacetic acid as starting materials, and undergoes six-step reactions of condensation, cyclization, nitrosation, reduction, cyclization, and bromine with a total yield of 46.3%. The structures of all intermediates were confirmed by 1HNMR.

The present invention relates to a simple preparation method of high-purity linagliptin. Quinazoline, the key intermediate for the one-pot preparation of linagliptin 8 bromo 7 (2 butyne 1 base) 3,7 dihydro 3 methyl 1 [(4 methyl 2 quinazolinyl) methyl] 1H Purine 2,6 dione, the intermediate is separated by filtration, and then reacted with (R)3 aminopiperidine dihydrochloride to obtain a solution containing linagliptin. After the solution containing linagliptin is processed again, Deliraliptin pure product. The preparation of the key intermediate of the present invention adopts a one-pot method, which is convenient to operate and improves the yield. After the key intermediate is separated, it is reacted with (R)3 aminopiperidine dihydrochloride, thereby Obtaining high-purity linagliptin also meets the production and declaration requirements of pharmaceutical companies to the greatest extent.


Product detail pictures:

Fixed Competitive Price K Series Polyacrylamide - 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3 – JIN DUN detail pictures


Related Product Guide:

With a sound enterprise credit history, exceptional after-sales services and modern production facilities, we've earned an outstanding track record amongst our consumers across the whole world for Fixed Competitive Price K Series Polyacrylamide - 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3 – JIN DUN , The product will supply to all over the world, such as: Ottawa, Montreal, Maldives, Our solutions have national accreditation standards for experienced, premium quality items, affordable value, was welcomed by people around the globe. Our goods will continue to increase in the order and look forward to cooperation with you, Really should any of those products be of interest to you, please letus know. We are going to be pleased to give you a quotation up on receipt of one's detailed specifications.
  • Managers are visionary, they have the idea of "mutual benefits, continuous improvement and innovation", we have a pleasant conversation and Cooperation.
    5 Stars By Dominic from Bolivia - 2017.09.29 11:19
    We have been appreciated the Chinese manufacturing, this time also did not let us disappoint,good job!
    5 Stars By Marguerite from Danish - 2017.04.28 15:45
    Write your message here and send it to us